Predictors of survival outcomes in patients with <i>MECOM EVI1</i> rearrangement aberrations in AML or MDS.
Yael Kusne(WinnMed), Cecilia Ysabel Arana Yi(Mayo Clinic Hospital), James M. Foran(Memorial Sloan Kettering Cancer Center), Jeanne Palmer(Mayo Clinic), Lisa Sproat(Mayo Clinic Hospital), Aref Al‐Kali(Mayo Clinic), Alyssa McGary(Mayo Clinic Hospital), Talha Badar(Mayo Clinic in Florida), Mark R. Litzow(Mayo Clinic in Arizona), Katalin Kelemen(Mayo Clinic Hospital), Patricia T. Greipp(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic)
Cited by 3
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Anthracycline Dose Intensification in Acute Myeloid Leukemia
|New England Journal of Medicine|2009|907